Last reviewed · How we verify
"Drug:Carvedilol" and "Drug:Ivabradine"
"Drug:Carvedilol" and "Drug:Ivabradine" is a Small molecule drug developed by IRCCS San Raffaele. It is currently FDA-approved.
Carvedilol and Ivabradine are marketed drugs developed by IRCCS San Raffaele, with a key composition patent expiring in 2028. The primary strength of these drugs lies in their established market presence and therapeutic efficacy. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | "Drug:Carvedilol" and "Drug:Ivabradine" |
|---|---|
| Sponsor | IRCCS San Raffaele |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- "Drug:Carvedilol" and "Drug:Ivabradine" CI brief — competitive landscape report
- "Drug:Carvedilol" and "Drug:Ivabradine" updates RSS · CI watch RSS
- IRCCS San Raffaele portfolio CI